Phase 4
N=22
Subantimicrobial Doxycycline in Acne
Acne Vulgaris · Pediatrics
Bottom Line
View on ClinicalTrials.gov: NCT05399290 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Apr 2023
Primary outcome: Primary: Patient Perceptions of Their Acne Treatment — 8; 8; 7; 7 score on a scale — p=0.677
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Doxycycline Hyclate (Drug)
- Age
- Pediatric · 13+ yrs
- Sex
- All
- Sponsor
- Michigan State University
- Primary completion
- Nov 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Perceptions of Their Acne Treatment |
8; 8; 7; 7; 8; 7 | 0.677 |
Summary
Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, clinicians can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. The investigators aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.
Eligibility Criteria
Inclusion Criteria
- Documented moderate to severe facial acne
Exclusion Criteria
- Other skin conditions on the face
- Previous antibiotic treatment for acne
- Use of antibiotics for any reason within the past month
- Use of new prescription regiment for acne within the last 3 months
- Positive pregnancy test in the clinic
- Cognitive impairments
Data sourced from ClinicalTrials.gov (NCT05399290). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.